Autonomix Medical, Inc. Common Stock

Autonomix Medical entered a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants covering 857,462 shares at $5.75 per share. The exercise is expected to generate about $4.9 million in gross proceeds before financial advisory fees and other offering expenses, with the transaction expected to close on or about August 26. As part of the agreement, Autonomix will issue the investor unregistered Series E-1 and Series E-2 warrants covering an aggregate of 1.07 million shares, each with an exercise price of $6.25 per share, exercisable immediately and expiring five years after issuance. The stock price more than doubled, jumping 116% to $11.63 on Monday after market hours.

Autonomix Medical Inc. has been issued U.S. Patent No. 12,433,670 covering systems that sense, map, and selectively target nerves associated with tumors, cancer-related pain, and autonomic nervous system disorders. The patent strengthens protection for the company's catheter-based microsurgical tools, which record neural signals and deliver energy or therapeutic agents to block or modulate tumor-associated nerves. The technology is intended to guide targeted therapy by mapping electrophysiological activity in nerves linked to tumor or metastatic cells, with potential applications spanning a wide range of solid tumors including pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers. CEO Brad Hauser said the patent represents another meaningful expansion of the company's intellectual property portfolio, reinforcing its strategy to build a comprehensive platform across oncology, organ function, and autonomic nervous system disorders. Shares of Autonomix, which have traded between $2.44 and $32.55 over the past year, closed Tuesday's regular session at $19.50, up 434.25%, and were at $15.22 in overnight trading, down 21.59%.

Autonomix Medical has been issued U.S. Patent No. 12,471,776, strengthening its intellectual property portfolio for precision neuromodulation. The patent covers systems, devices, and methods for monitoring physiologic signals to assess autonomic nervous system activity, including technologies for evaluating sympathetic and parasympathetic function through multiple assessment techniques. It also encompasses innovations that may support patient selection, procedural guidance, treatment feedback, and post-treatment monitoring across a broad range of neuromodulation applications. CEO Brad Hauser stated the patent protects innovations designed to improve the precision and effectiveness of future nerve-targeted therapies, reinforcing the company's vision of building a differentiated technology platform for diseases involving the peripheral nervous system.

Autonomix Medical has been granted a US patent covering its platform for diagnosing and treating overactive bladder. The patent, issued by the US Patent and Trademark Office, expands the company's neural sensing and therapeutic technology into the urology market, where overactive bladder affects an estimated 37 million Americans. The platform supports a catheter-based, minimally invasive approach that detects abnormal bladder nerve activity and delivers targeted therapy such as radiofrequency ablation or localized drug delivery, with real-time electrophysiological feedback to verify treatment effectiveness. The patent also covers an implantable bladder device for long-term monitoring of bladder pressure and electrophysical signals. CEO Brad Hauser said the patent strengthens the company's intellectual property portfolio in nerve-targeted therapies.

Autonomix Medical has entered into a warrant inducement agreement with an existing investor expected to generate about $2.6 million in gross proceeds through the immediate exercise of warrants. Under the agreement, the investor will exercise November 2025 warrants to purchase 428,731 common shares at an amended exercise price of $6.00 per share. In exchange, Autonomix will issue two new unregistered warrant series, D-1 and D-2, each exercisable for 428,731 shares at an exercise price of $5.75 per share. The transaction is expected to close on or about July 15, with proceeds used for working capital and general corporate purposes.